HIV algorithm

• Messages sorted by: [ date ][ thread ][ subject ][ author ]
• Next message: kukuruga%kasle1.dnet.wayne.edu@rocdec.roc.wayne.edu: "RE: Isotype controls"
• Previous message: Alice L. Givan: "isotype controls"

I realize that strategies for therapy and monitoring disease in HIV infection is
in a state of flux, but I have been asked to develop an algorithm for an HMO,
and I wonder if the NIH panel recommendations of a few years ago are still
timely. Are decision points for treatment and monitoring still focus on CD4
counts of 500/ul and 200/ul for anti-retroviral and PCP prophylaxis,
respectively? Any recent references would be appreciated.

Thanks,
D.A.Sadler, MD

• Next message: kukuruga%kasle1.dnet.wayne.edu@rocdec.roc.wayne.edu: "RE: Isotype controls"
• Previous message: Alice L. Givan: "isotype controls"

CD ROM Vol 2 was produced by staff at the Purdue University Cytometry Laboratories and distributed free of charge as an educational service to the cytometry community. If you have any comments please direct them to Dr. J. Paul Robinson, Professor & Director, PUCL, Purdue University, West Lafayette, IN 47907. Phone:(317) 494-0757; FAX (317) 494-0517; Web http://www.cyto.purdue.edu EMAIL robinson@flowcyt.cyto.purdue.edu